Placebo for ABT-333

DRUG3 trials

Sponsors

AbbVie (prior sponsor, Abbott)

Conditions

Chronic Hepatitis C InfectionChronic Hepatitis C Virus Infection

Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT00851890

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Virus Infection

Start: 2009-03-31End: 2009-07-31Updated: 2018-07-02

Phase 3

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

CompletedNCT01715415

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-11-30End: 2014-10-31Updated: 2021-08-02

A Study to Evaluate Chronic Hepatitis C Infection

CompletedNCT01716585

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-11-30End: 2014-10-31Updated: 2021-07-12

Related Papers

Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen.

2018-01-0139 citations

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

New England Journal of Medicine2014-04-11899 citations

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

New England Journal of Medicine2014-04-10514 citations